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Background: Nephrotic syndrome (NS) and proteinuria are uncommon, often unrec-
ognized manifestations of graft-versus-host disease (GVHD) after hematopoietic stem
cell transplantation (HSCT). Only a few isolated case reports and case series involving
smaller number of patients who developed NS after HSCT have been published.
Methods: We reviewed the renal histopathological examination ﬁndings and clinical
recordsof15patientswhodevelopedproteinuria afterHSCTat Seoul andYeouidoSt.Mary′s
Hospital (Seoul, Korea). We also measured the anti-PLA2R antibodies (M-type phospholi-
pase A2 receptor) in the serum samples from the sevenpatients at the time of renal biopsy.
Results: All patients had GVHD. The most common indication for biopsy was
proteinuria (41 g/day), with nine patients having nephrotic range proteinuria. The
most common histopathological ﬁndingwasmembranous nephropathy (MN; n ¼ 12).
Other ﬁndings were membranoproliferative glomerulonephritis, C1q nephropathy,
and diabetic nephropathy. Eleven patients were treated with immunosuppressive
agents, and three patients were treated only with angiotensin II receptor blocker. The
overall response rate, including complete remission (urinary protein levelo0.3 g/day)
and partial remission (urinary protein level ¼ 0.31–3.4 g/day), was 73%. The mean
follow-up period was 26 months, and none of the patients developed end-stage renal
disease. All of the seven patients with MN had negative ﬁndings for anti-PLA2R
antibodies, measured using an enzyme-linked immunosorbent assay kit.
Conclusion: In this study the ﬁndings of 15 renal biopsies were analyzed and to our
knowledge this is the largest clinicopathological study of GVHD-related biopsy-proven
nephropathy. Approximately 80% of the patients were MN and 73% responded either
partially or completely to immunosuppressive treatment. Currently, there is an increase in
the incidence of GVHD-mediated renal disease, and therefore, renal biopsy is essential for
diagnosing the nephropathy and preventing the progression of renal disease.
& 2013. The Korean Society of Nephrology. Published by Elsevier. This is an open access
article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).n Society of Nephrology. Published by Elsevier. This is an open access article under the CC BY-NC-ND
c-nd/4.0/).
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Hematopoietic stem cell transplantation (HSCT) is an effec-
tive therapy for patients who require potent chemotherapy
drugs for the treatment of certain diseases such as acute
leukemia. The development of new chemotherapeutic agents
and better control of infection have improved the survival rate
of patients who undergo HSCT; however, these measures have
also introduced certain long- and short-term complications.
Chronic graft-versus-host disease (cGVHD) is a common late
complication of allogeneic HSCT that occurs in 60–80% of long-
term survivors, and its incidence is currently increasing [1].
In animal models, the kidney was deﬁned as a target organ
of cGVHD, but the underlying mechanisms and pathogenesis
of GVHD-related renal disease in people are unclear [2].
The recognized renal problems in HSCT recipients are drug
toxicity, radiation nephritis, infection, thrombotic microangio-
pathy, and glomerulonephritis. The etiology and pathogenesis
of proteinuria, including nephrotic syndrome (NS) in HSCT
recipients remain unclear; however, an association between
NS and cGVHD has been proposed. Brukamp K, Doyle AM,
Bloom RD, Bunin N, Tomaszewski JE, and Cizman B [3] have
reported that membranous nephropathy (MN) accounts for
two-thirds and minimal change disease (MCD) accounts for
one-third of the cases of NS in HSCT recipients. Renal biopsy is
rarely performed after HSCT because of inappropriate general
conditions and patients’ reluctance. Therefore, only a fewTable 1. Clinical and histopathological ﬁndings of the 15 patient
transplantation
Patient Age (y)/
Gender
Original
disease
Type of HSCT,
interval of
KB (mo)
Time between
drug nwithdrawal
and KB (mo)
Conditionin
regimen
1 31/F CML Allo-BMT, 44 15 CY, TBI
2 51/F CML Allo-BMT, 64 AZP CY, FB
3 48/M AML Allo-BMT, 12 3 CY, TBI
4 35/F AML Allo-BMT, 20 19 CY, TBI
5 39/M ALL Allo-BMT, 43 0 Ara-C, MP,
TBI
6 40/M ALL Allo-BMT, 14 6 CY, TBI
7 35/F AA Allo-BMT, 42 Pre CY, TBI
8 30/M ALL Allo-BMT, 16 Pre CY, TBI
9 56/M AML Allo-PBSCT, 8 CsA CY, TBI
10 47/F AML Allo-PBSCT, 47 CsA, MMF CY, TBI
11 21/F ALL Allo-PBSCT, 11 3 CY, TBI
12 42/M ALL Allo-BMT, 111 89 Ara-C, MP,
TBI
13 35/M ALL Allo-BMT, 24 10 CY, TBI
14 40/M MDS Allo-BMT, 144 94 BU, TBI
15 45/M AML Allo-PBSCT, 23 MMF, Pre BU, FB, TBI
n Immunosuppressive agents including prednisolone, cyclosporine, mycophe
A, acute; AA, aplastic anemia; Allo-BMT, allogeneic bone marrow transplant
Ara-C, cytarabine; ARB, angiotensin II receptor blocker; AZP, azathioprine; B
(mg/dL); CR, complete remission; CsA, cyclosporine; CY, cyclophosphamide
graft-versus-host disease; HSCT, hematopoietic stem cell transplantation;
nephropathy; mo ¼ months; MP, melphalan; MPGN, membranoproliferativ
plasma exchange; PR, partial response; Pre, prednisolone; PU, proteinuria; Treports of renal histopathological analysis after allogeneic
HSCT are available in the literature, and these consist of only
case reports or case series involving smaller number of
patients.
In this study, we have analyzed the clinicopathological
characteristics of 15 HSCT recipients having urinary protein
levels 41 g/day. To our knowledge, this is the largest series
assessing patients with biopsy-proven nephropathy
after HSCT.Methods
We reviewed the renal pathology records of the patients at
Seoul and Yeouido St. Mary′s Hospital (Seoul, Korea) and
identiﬁed 15 renal biopsy specimens from 15 patients obtained
after allogeneic HSCT between January 2000 and January 2013.
During that period, approximately 2,800 procedures of allo-
geneic HSCT were performed. The renal biopsy specimens were
routinely divided into three portions for examination: (1) tissues
ﬁxed in 10% formalin and embedded in parafﬁn, after which 3-
μm thick sections were cut and stained with hematoxylin and
eosin, periodic acid-Schiff, silver methenamine, and Masson′s
trichrome. The sections were viewed using light microscopy
(LM); (2) the tissue section was ﬁxed in glutaraldehyde and
examined under an electron microscope (EM); and (3) the tissue
was examined with direct immunoﬂuorescence microscopy (IF)s with graft-versus-host disease after hematopoietic stem cell
g GVHD Clinical
indication
of KB
Diagnosis Treatment
A and C (eye, gut,
liver, skin)
NS; PU ¼ 4.9 g MN Pre
C (lung) NS; PU ¼ 5.6 g MN ARB
A and C (liver,
oral, skin)
NS; PU ¼ 7 g MN CsA
C (eye, oral) NS; PU ¼ 5.2 g MN Pre
A and C (gut
and lung)
Proteinuria; PU
¼ 3.1 g
MN Pre
C (joint) NS; PU ¼ 11.9 g MN Pre and
ARB
A and C (gut, oral) Proteinuria; PU
¼ 3.2 g
MN CsA
A and C (gut and
skin)
Proteinuria; PU
¼ 2.6 g
MN Pre and
ARB
A and C (eye, liver,
oral, skin)
Proteinuria; PU
¼ 1.1 g
MN ARB
A and C (oral, liver,
skin)
NS; PU ¼ 7.9 g MN Pre and
ARB
A and C (liver,
oral)
NS; PU ¼ 4.6 g MN Pre and
ARB
C (eye, oral) Proteinuria; PU
¼ 2.3 g
MN ARB
A and C (gut, skin,
oral)
NS; PU ¼ 4.2 g MPGN type 1 Pre, ARB
and AZP
A and C (eye, skin) Proteinuria; PU
¼ 2.4 g
Diabetic
nephropathy
ARB
A and C (liver) NS; PU ¼ 7.6 g C1q
nephropathy
Pre and
ARB
nolate mofetil, and azathioprine.
ation; Allo-PBSCT, allogeneic peripheral blood stem cell transplantation;
U, busulfan; C, chronic; CML, chronic myeloid leukemia; Cr, creatinine
; FB, ﬂudarabine; FPGN, focal proliferative glomerulonephritis; GVHD,
KB, kidney biopsy; MMF, mycophenolate mofetil; MN, membranous
e glomerulonephritis; NR, nonresponder; NS, nephrotic syndrome; PE,
BI, total body irradiation.
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ﬁbrinogen, and light chains. Data concerning the patient
characteristics, clinical course, and outcome were collected from
their medical records. Responses to treatment were categorized
as complete remission (CR), partial remission (PR), or nonre-
sponse. The CR and PR were deﬁned as a reduction of urinary
protein levels to o0.3 g/day and urinary protein levels between
0.31 g/day and 3.4 g/day, respectively [4]. We measured the anti-
PLA2R (M-type phospholipase A2 receptor) antibodies using a
commercial antigen-speciﬁc enzyme-linked immunosorbent
assay (ELISA) kit (MyBioSource Inc., San Diego, CA, USA) in the
serum samples from seven patients at the time of renal biopsy.Results
Patient characteristics and histopathological biopsy ﬁndings
Patient clinical features and histopathological ﬁndings of
the renal biopsies are summarized in Table 1. The incidence of
biopsy-proven renal disease, including NS, was approximately
0.5% (15 cases among a total of 2,800 allogeneic HSCT
recipients). A total of 15 renal biopsies from 15 patients who
had previously undergone allogeneic HSCT were examined.
The mean age of the patients was 39 years (range: 21–56
years), and nine of the 15 patients were male. All patients had
normal renal function prior to the HSCT and absence of
proteinuria. Cases 3, 14, and 15 had a history of diabetes
mellitus without proteinuria and Case 14 had chronic hepatitis
B and they all received lamivudine prior to undergoing HSCT.
The mean duration between HSCT and renal biopsy was
40 months (range: 8–144 months). The underlying diseases
resulting in the need for HSCT were acute lymphoid leukemia,
six patients; acute myeloid leukemia, ﬁve patients; chronic
myeloid leukemia, two patients; aplastic anemia, one patient;
and myelodysplastic syndrome, one patient (Fig. 1). cGVHD
was deﬁned as pathological ﬁndings when it appeared 100
days after allogeneic HSCT. All cGVHD events were preceding
the onset of proteinuria. Six of the 15 patients were taking
immunosuppressive agents at the time of kidney biopsy
(Table 2). The most common indication for biopsy was0
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Figure 1. The underlying hematologic diseases in hematopoietic
stem cell transplantation patients who received renal biopsies for
either nephrotic syndrome (NS) or non-nephrotic range proteinuria.
AA, aplastic anemia; ALL, acute lymphoid leukemia; AML, acute myeloid
leukemia; CML, chronic myeloid leukemia; MDS, myelodysplastic
syndrome.proteinuria, which was present in all patients; the urinary
protein levels were within the nephrotic range in nine patients
(Fig. 1).
Renal histopathological ﬁndings
The most common histopathological ﬁnding was MN (n ¼
12). Other glomerular diseases identiﬁed were membranopro-
liferative glomerulonephritis (MPGN), C1q nephropathy, and
diabetic nephropathy. Among the patients who had MN, seven
had full-blown NS. Biopsy specimens from the MN patients
indicated typical pathological features of the disease including
thickening of basement membrane on LM (Fig. 2A) and ﬁne
granular deposit of IgG and C3 on IF; moreover, EM indicated
the presence of electron-dense, subepithelial immune deposi-
tion (Fig. 2B). Renal biopsies from these patients did not
demonstrate interstitial ﬁbrosis with tubular atrophy and
inﬂammatory cell inﬁltration.
The renal biopsy specimen of a patient (Case 13) indicated
diffuse global capillary wall thickening and mesangial expan-
sion on LM and subendothelial and mesangial electron-dense
deposit on EM. The IF indicated IgG and IgM deposition in the
glomerular basement membrane (GBM) and mesangium.
Thus, the patient was diagnosed with type 1 MPGN (Table 1).
The renal biopsy specimen of another patient (Case 14)
indicated global glomerular sclerosis in 50% of glomeruli and
moderate mesangial expansion. Because this patient had type
2 diabetes, the diagnosis of diabetic nephropathy was made. The
renal biopsy specimen of another patient (Case 15) indicated
mesangial cell proliferation associated with mesangial deposits
on EM and C1q deposition on IF; these ﬁndings were compatible
with the diagnosis of C1q nephropathy.
Results of anti-PLA2R antibody measured using ELISA kit
The serum samples of seven patients with MN were
collected at the time of renal biopsy and their anti-PLA2R
titers were measured. All study patients had negative ﬁndings
for anti-PLA2R antibodies.
Response to treatment and clinical course
The patient responses to treatment, determined based on
follow-up tests of renal functions [serum creatinine and
estimated glomerular ﬁltration rate (GFR) levels, which were
calculated using the Modiﬁcation of Diet in Renal Disease
formula (MDRD estimated GFR)], is summarized in Table 2.
End-stage renal disease (ESRD) did not develop in any patient.
Nine patients with MN were treated with prednisolone (2 mg/kg)
that was administered on alternative days. Two patients with MN
did not respond to prednisolone therapy, and therefore, additional
treatment involving cyclosporine was initiated. A patient (Case 2),
who had been previously treated with azathioprine developed
bronchiectasis and recurrent infections associated with pulmonary
GVHD; therefore, this patient was not treated with other immu-
nosuppressive agents. However, we lost this patient to follow-up
and was thus considered a nonresponder. Another patient
(Case 9), who was receiving cyclosporine prior to being diagnosed
with MN, was treated with angiotensin II receptor blocker (ARB)
and achieved PR. Moreover, a patient (Case 12) who was treated
with only ARB achieved PR. Among the 12 patients with MN, the
CR rate was 25% and the PR rate was 58%. In a patient (Case 13)
with MPGN type 1, initial treatment with prednisolone was
Figure 2. Renal biopsy ﬁndings from a patient with membranous
nephropathy. (A) A light micrograph illustrating preserved glomerular
architecture, but thickened capillary walls (Periodic acid-Schiff stain
400X). (B) An electron micrograph illustrating electron-dense sube-
pithelial deposits and effacement of epithelial cell foot processes
(6,000X).
Table 2. Patient responses to treatment and follow-up renal function
Patient Renal disease Cr (mg/dL) MDRD eGFR Treatment response Follow-up
duration (mo)
At the time of KB Follow-up At the time of KB Follow-up
1 MN 0.73 0.65 96 107 CR 59
2 MN 0.51 0.52 135 132 NR 17
3 MN 0.82 1.2 107 68 PR 30
4 MN 0.54 0.73 137 95 CR 31
5 MN 1.23 1.31 69 64 PR 34
6 MN 0.83 1.83 109 43 NR 29
7 MN 0.73 0.91 96 73 CR 24
8 MN 0.73 0.69 133 139 PR 43
9 MN 1.19 1.27 49 45 CR 39
10 MN 0.74 0.62 89 109 CR 5
11 MN 0.44 0.46 191 182 PR 3
12 MN 1.17 1.52 72 53 CR 21
13 MPGN 1.55 1.27 55 68 PR 6
14 Diabetic nephropathy 2.02 Follow-up loss 39 Follow-up loss Follow-up loss Follow-up loss
15 C1q nephropathy 1.49 2.00 54 38 Death Death
CR, complete remission; MDRD eGFR; estimated glomerular ﬁltration rate using the Modiﬁcation of Diet in Renal Disease formula; MN, membranous
nephropathy; MPGN, membranous proliferative glomerulonephritis; PR, partial remission.
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azathioprine. This patient achieved PR. A patient (Case 14) with
diabetic nephropathy was referred to a local clinic for further
treatment, whereas another patient (Case 15) with C1q nephro-
pathy died from sepsis due to complications of GVHD 2 weeks
after undergoing renal biopsy.Discussion
The outcomes of HSCT recipients have improved due to the
development of novel chemotherapeutic agents, effective pre-
vention, and treatment of infections, and new transplant
regimens, such as nonmyeloablative transplantation. However,
this improvement has been accompanied by an increase in
glomerular or interstitial renal disease.
All our patients exhibited evidence of acute GVHD or
cGVHD, which was present prior to or simultaneously with
the renal disease. The GVHD frequently affects the skin, oral
mucosa, liver, and gastrointestinal tract. The pathophysiology
of GVHD is not well understood. In a murine model of cGVHD,
renal involvement of cGVHD has been commonly detected;
however, renal involvement of cGVHD in humans has been
rarely noted [5]. Inﬂammatory and cytokine cascade, such as
those involving tumor necrosis factor-α and/or interferon-γ,
from donor T cell may be crucial for the development of the
renal disease in cases with GVHD [6]. Brukamp K, Doyle AM,
Bloom RD, Bunin N, Tomaszewski JE, and Cizman B [3] have
proposed that withdrawal or reduction in the dose of immu-
nosuppressive agents in GVHD treatment is a risk factor for the
development of NS.
Among the different types of glomerulopathies, MN is
reportedly the most common, followed by MCD [7], which is
consistent with the ﬁndings of this study as well (80%). The
overall response rate (CR and PR) was 73%. At present, there are
no standard treatment guidelines for NS after HSCT. Niscola P,
Tendas A, Luo XD, Catalano G, Scaramucci L, Cupelli L, Giovan-
nini M, Ferranini M, Bondanini F, Piccioni D, Dentamaro T,
Palumbo R, Perrotti AP, Liu QF, and de Fabritiis P [7] analyzed
69 previously reported cases of MN and found that the treat-
ments used were very highly variable, the most frequently used
agent was corticosteroid followed by cyclosporine. In that study,
Cho et al / Nephrotic syndrome after HSCT 12559% patients achieved CR and 28% achieved PR. Treatment failed
in the remaining 13% of patients, and ESRD developed in a few
patients [7]. In this study, the combined response rate of CR and
PR in patients with MN was 73%, which is similar to that
previously reported [7]. Approximately 30–35% of untreated
patients with idiopathic MN have benign course of the disease
or spontaneous resolution, and the decision to initiate treat-
ment using immunosuppressive agent should be made based
on the patients’ risk factor such as proteinuria levels or
deteriorating of renal function [4]. However, in patients with
secondary MN, the treatment of the underlying disease induced
a remission of MN (e.g., the treatment of neoplasm in case of
malignancy-associated MN). Therefore, we initiated the immu-
nosuppressive agent treatment in all the patients with MN, in
order to treat the renal GVHD.
MN is the most common form of immune-complex-
mediated glomerulonephritis reported in association with
HSCT [6–8]. MN is caused by the deposition of immune
complexes in the subepithelial zone of glomerular capillaries,
but its underlying pathogenic mechanism is not completely
understood. The role of anti-PLA2R (M-type phospholipase A2
receptor) antibodies in primary MN has recently been eluci-
dated [9]. Although anti-PLA2R antibody was detected in
approximately 70% of patients with primary MN, some
patients with secondary MN also exhibited the antibody.
Moreover, Qin W, Beck LH Jr, Zeng C, Chen Z, Li S, Zuo K,
Salant DJ, and Liu Z. [10] detected anti-PLA2R antibody in 6.3%
of patients with hepatitis B virus-associated MN and in 30% of
patients with tumor-associated MN. By contrast, the etiology
and signiﬁcance of anti-PLA2R antibody in secondary MN are
not known, especially in HSCT with GVHD. Moreover, the
relationship between serum concentration of the antibody
and the clinical course of MN is unknown and requires
additional investigation. In our study, seven patients whose
serum samples were collected at the time of renal biopsy had
negative results for the anti-PLA2R antibodies in the ELISA test.
This result suggests that MN associated with GVHD has a
different pathogenesis from idiopathic MN. It has been well
known that the antibody directed against tubular brush-
border antigen induced tubulointerstitial ﬁbrosis and tubular
atrophy in a murine GVHD model [11]. However, our patients
with MN did not show a prominent tubular injury, because
they were in the early phase of MN.
In addition to MN, the other common glomerulopathy was
MCD. MCD accounts for approximately one-quarter of the
cases of NS after HSCT [3,12]. The treatment response of
patients with MCD is better than that of MN patients, with a
previous study reporting that 90% of its study patients had
achieved CR [3]. In this study, however, none of the patients
had MCD. One of our patients had MPGN type 1 and was
successfully treated with prednisolone and azathioprine. In
addition, a patient with C1q nephropathy died from GVHD-
associated sepsis.
Although the mechanisms underlying the development of
NS or proteinuria associated with GVHD have not been
elucidated, it has been hypothesized to represent the end
stage of alloreactivity, in which T cells have evolved to assume
the Th2 phenotype [13,14]. A proposed mechanism for this
evolution is immune dysregulation resulting from the transfer
of alloreactive peripheral donor lymphocytes (possibly, CD8+/
perforin+ cytotoxic T cells) present in the primary blood stem
cell graft, with reactivity toward glomerular antigens [15]. The
CD8+/perforin+ cytotoxic T lymphocytes might induce thedestruction of glomeruli and apoptosis of podocytes and
endothelial cells, producing microthrombi, and ﬁnally destroy-
ing the loop segments [15]. Another hypothesis is that the
induction of GVHD in rats may lead to restricted polyclonal
stimulation of B cells and the formation of autoantibodies
directly targeting basement membrane. Consequently, immu-
noglobulin deposition along the GBM and development of
proteinuria were found [11].
In summary, we have analyzed the clinicopathological
features of 15 patients who have developed proteinuria or
NS in association with GVHD after allogeneic HSCT. The most
common histopathological renal ﬁnding was MN and most
patients with MN responded well to immunosuppressive
agents. Because the population of long-term survivors after
allogeneic HSCT is growing, the incidence of GVHD-mediated
renal disease may increase. Therefore, renal biopsy is essential
in establishing the cause of the renal dysfunction and in
directing the proper immunosuppressive therapy.Conﬂicts of interest
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